What are the side effects and contraindications of Sunitinib?

Based on the clinical trial study of sunitinib (Sunitinib) on gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and advanced pancreatic neuroendocrine Oncology (pNET) data showed that the most common adverse reactions (≥25%) of sunitinib were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/taste changes, dyspepsia, and thrombocytopenia.

After marketing, common adverse reactions of sunitinib include thrombocytopenic bleeding, esophagitis, cholecystitis, allergic reaction (angioedema), serious infection (with or without neutropenia), respiratory tract, urinary tract, skin infection and sepsis/Septic shock, fistula formation, myopathy and/or rhabdomyolysis with or without acute renal failure, renal damage and/or failure, poor wound healing, etc.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. The price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.